|Bid||1.1800 x 4000|
|Ask||1.2000 x 3200|
|Day's range||1.1300 - 1.2300|
|52-week range||0.5800 - 4.7600|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.
Cancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a monotherapy for ovarian cancer in the initial part of a phase 3 trial. All told, 538 women suffering from high-grade ovarian, fallopian tube, or primary peritoneal cancer took part in the trial.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.